

*THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR  
DISSEMINATION IN THE UNITED STATES*

**SUPER NOVA PETROLEUM CORP.**

**CSE (CNSX): SNP  
OTC: SNOVF**

**NEWS RELEASE**

**SUPER NOVA ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION AND  
CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT**

Vancouver, BC, December 18, 2017 - Super Nova Petroleum Corp. (CSE/CNSX: SNP; OTC: SNOVF) (the "Company" or "Super Nova") announces that, further to the news releases dated September 29, October 23, 2017, October 30, 2017 and November 30, 2017, the Company has closed the third and final tranche of its \$2 million non-brokered private placement. The third tranche consisted of the sale of 425,000 subscription receipts (each, a "Subscription Receipt") for gross proceeds of \$85,000. In the event that the Company completes the purchase of Koios, LLC ("Koios") (the "Transaction") on or before January 31, 2018, each Subscription Receipt will be automatically converted, for no additional consideration, into one common share (each, a "Share") of the Company. The Company has agreed to pay an aggregate of \$3,600 in finders' fees in connection with the third tranche. The Company exercised its over-allotment option and raised a total of \$2,380,000 from the closing of the first, second and third tranches of the Financing.

On release from escrow, the net proceeds from the financing will allow Koios to start producing next generation products, through advanced research and development. Koios intends on expanding its product line to meet consumer demand and to be more competitive on store shelves and intends on expanding its current sales force to capitalize on retail growth and drive bottom line revenue. Koios also intends on expanding its digital presence through increased marketing and progressive ecommerce strategies.

Each Share issued upon conversion of the Subscription Receipt will be subject to a hold period expiring four months and one day after the closing of each tranche of the private placement.

Conditions of the Transaction

Completion of the Transaction remains subject to, among other things, satisfactory due diligence by the parties, approval of the CSE, completion of the financing, approval of the shareholders of the Company and other conditions which are customary for transactions of this nature.

About Koios

Koios is an emerging functional beverage company whose products are currently available in over 2,000 retail locations across the country. Koios has relationships with some of the largest and most reputable distributors in the country; Europa Sports, Muscle Foods USA, KeHE, and

Wishing-U-Well. Together these distributors represent over 80,000 brick and mortar locations across the United States from sports nutrition stores to large natural grocery chains including Whole Foods and Sunflower markets. Through our partnership with Wishing-U-Well, Koios also enjoys a large presence online, including being an Amazon choice product.

Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants.

Koios enhances focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and creates all day mental clarity. Our ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.

Koios is one of the only drinks in the world to infuse its products with MCT oil. MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, creates lasting energy from a natural food source, produces ketones in the brain, allowing for greater brain function and clarity, supports healthy hormone production and improves immunity.

On behalf of the Board of Directors of the Company.

**SUPER NOVA PETROLEUM CORP.**

“Wolf Wiese”

Wolf Wiese, President & CEO

For further information, please contact:

Corporate Communications  
604-221-8936

*Completion of the Transaction is subject to a number of conditions, including CSE acceptance. There can be no assurance that the Transaction will be completed as proposed or at all.*

*Investors are cautioned that any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Super Nova should be considered highly speculative.*

*The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release.*

**Forward-Looking Statements**

*This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding: the closing of the Transaction and the expected use of proceeds thereof. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements.*

*Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include, among other things: that the CSE or the Company's shareholders may not approve the Transaction as proposed or at all; that the parties may not be able to satisfy the conditions to closing of the Transaction; general market conditions; and other factors beyond the control of the parties. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.*

*Koios has not conducted any scientific studies on the effects of Koios' products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios' products will vary from person to person. No claims or guarantees can be made as to the effects of Koios' products on an individual's health and wellbeing.*